• About Us
    • Company History
    • Our Mission
    • Management Team
    • Board of Directors
  • Technology
    • The Problem
    • The Solution: Our Microbial Platforms
      • C1
      • Dapibus™
    • Advantages and Opportunities
  • Pipeline
    • Human Health
    • Animal Health
    • Alternative Proteins
  • Partners
  • Investors
    • Overview
    • Press Releases
    • SEC Filings
    • Financials
    • Investor Fact Sheet
    • Analyst Coverage
    • Corporate Governance
    • Annual Meeting and Proxy
    • Stock Information
    • Earnings Calls
    • Email Alert Opt-in
  • Media
    • Articles
    • Events
    • Presentations
    • Press Releases
    • Scientific Publications
    • Video Gallery
  • Contact Us

Dyadic to Participate at Two Industry Events in May

by B2i | May 10, 2023 | Press Releases

JUPITER, Fla., May 10, 2023 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...

Dyadic Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus™

by B2i | May 8, 2023 | Press Releases

JUPITER, Fla., May 08, 2023 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms...

Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

by B2i | Apr 26, 2023 | Press Releases

JUPITER, Fla., April 26, 2023 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...

Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform

by B2i | Apr 18, 2023 | Press Releases

JUPITER, Fla., April 18, 2023 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein...

Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent

by B2i | Apr 12, 2023 | Press Releases

JUPITER, Fla., April 12, 2023 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein...

Dyadic to Present at World Vaccine Congress Washington 2023

by B2i | Mar 30, 2023 | Press Releases

JUPITER, Fla., March 30, 2023 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...
« Older Entries
Next Entries »

Recent Posts

  • Dyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company Progress
  • Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
  • Dyadic to Present at World Vaccine Congress | Washington
  • Dyadic Reports 2024 Year-End Financial Results and Business Updates
  • Dyadic Announces Funding Award from CEPI to Use C1 to Accelerate Development of Protein-Based Vaccines

Recent Comments

No comments to show.

Sign up for communications from Dyadic

Stay informed and receive company updates straight to your inbox.

Signup

Dyadic International, Inc. (NASDAQ: DYAI) is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical and bio-industrial products for human and animal health and alternative proteins.

  • About Us
    • Company History
    • Our Mission
    • Management Team
    • Board of Directors
  • Technology
    • The Problem
    • The Solution: Our Microbial Platforms
      • C1
      • Dapibus™
    • Advantages and Opportunities
  • Pipeline
    • Human Health
    • Animal Health
    • Alternative Proteins
  • Partners
  • Investors
    • Overview
    • Press Releases
    • SEC Filings
    • Financials
    • Investor Fact Sheet
    • Analyst Coverage
    • Corporate Governance
    • Annual Meeting and Proxy
    • Stock Information
    • Earnings Calls
    • Email Alert Opt-in
  • Media
    • Articles
    • Events
    • Presentations
    • Press Releases
    • Scientific Publications
    • Video Gallery
  • Contact Us
© 2025 Dyadic International Inc